

6 августа 2021 г.

## Landscape of candidate vaccines in clinical development

**DISCLAIMER:** These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

New information that has been added this week is highlighted in yellow

(NCT04510207) This Phase 3 trial assesses both the Wuhan and Beijing vaccine in the same study.

\*Pending confirmation on the phase of study which is not specified in the registry.

\*\* Trials that have indicated assessment of vaccine efficacy against SARS-CoV-2 variants.

The information provided is taken directly from data available in the trial registries. In cases where the trial is registered as N/A or without a defined clinical phase, it has been listed in the column "Phase not reported".

TBD (To be defined)

Information highlighted in red indicates a change in the development of the vaccine

ID	Vaccine platform acronym	Vaccine platform description	Type of candidate vaccine	Number of doses	Schedule	Route of administration	Developers	Phase
90	PS	Protein subunit	Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)	2	Day 0 + 21	IM	Guangdong Provincial Center for Disease Control and Prevention/Gaozhou	Phase 2
91	RNA	RNA based vaccine	HDT-301: Self-replicating mRNA vaccine formulated as a lipid nanoparticle.	2	Day 0 + 28	IM	SENAI CIMATEC	Phase 1
92	IV	Inactivated Virus	Adjuvanted inactivated vaccine against SARS-CoV-2	2	Day 0 + 21	SC	The Scientific and Technological Research Council of Turkey (TÜBİTAK)	Phase 1
93	RNA	RNA based vaccine	mRNA-1283	2	Day 0 + 28	IM	ModernaTX, Inc.	Phase 1
94	PS	Protein subunit	Recombinant SARS-CoV-2 Vaccine (CHO cell)	2	Day 0	IM	National Vaccine and Serum Institute, China	Phase 1/2
95	RNA	RNA based vaccine	EXG-5003; a temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein.	1	Day 0	ID	Elixirgen Therapeutics, Inc	Phase 1/2
96	IV	Inactivated Virus	Inactivated COVID-19 vaccine	2	Day 0 + 28	IM	KM Biologics Co., Ltd.	Phase 1/2
97	IV	Inactivated Virus	Live recombinant Newcastle Disease Virus (rNDV) vector vaccine	2	Day 0 + 21	IM or IN	Laboratorio Avi-Mex	Phase 1
98	RNA	RNA based vaccine	mRNA COVID-19 vaccine	2	TBD	IM	Shanghai East Hospital and Stemirna Therapeutics	Phase 1
99	PS	Protein subunit	CoVepi vaccine: SARS-CoV-2 multi-target peptide vaccine (targeting Spike, M, N, and several non-structural proteins)	1-2	Day 0 +/- 21	SC	OSE Immunotherapeutics	Phase 1
100	VVnr	Viral vector (Non-replicating)	Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized SARS-CoV-2 spike protein	2	Day 0 + 28	IM	German Center for Infection Research	Phase 1/2
101	PS	Protein subunit	CoV2-OGEN1, protein-based vaccine	1-2	Day 0 +/- 14	Oral	USSF/Vaxform	Phase 1
102	PS	Protein subunit	QazCoVax-P - COVID-19 Subunit Vaccine	1-2	Day 0 + 21	IM	Research Institute for Biological Safety Problems	Phase 1/2
103	RNA	RNA based vaccine	LNP-nCoV saRNA-02 vaccine; Self-amplifying RNA (saRNA) encapsulated in lipid nanoparticles (LNP)	2	Day 0 + 28	IM	MRC/UVRI and LSHTM Uganda Research Unit	Phase 1
104	RNA	RNA based vaccine	mRNA-1273.211. A multivalent booster candidate combining mRNA-1273 plus mRNA-1273.351.	1	Day 0	IM	ModernaTX, Inc.	Phase 2/3
105	PS	Protein subunit	RBD protein recombinant SARS-CoV-2 vaccine	3	Day 0 + 21 + 35	IM	Bagheiat-allah University of Medical Sciences	Phase 1
106	PS	Protein subunit	Baiya SARS-CoV-2 VAX1, a plant-based subunit vaccine (RBD-Fc + adjuvant)	2	Day 0 + 21	IM	Baiya Phytopharm Co., Ltd.	Phase 1
107	PS	Protein subunit	SCB-2020S, an adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351 variant)	2	Day 0 + 21	IM	Clover Biopharmaceuticals AUS Pty Ltd	Phase 2
108	VVnr	Viral vector (Non-replicating)	PIV5 vector that encodes the SARS-CoV-2 spike protein	1	Day 0	IN	CyanVac LLC	Phase 1
109	VVnr	Viral vector (Non-replicating)	AZD2816; adenoviral vector ChAdOx platform and based on the Beta (B.1.351) variant	2	Day 0 + 28	IM	AstraZeneca + University of Oxford	Phase 2/3
110	PS	Protein subunit	202-CoV; SARS-CoV-2 spike trimer protein + adjuvant, CpG7909.	2	Day 0 + 28	IM	Shanghai Zerun Biotechnology + Walvax Biotechnology + CEPI	Phase 1